We considered that a regimen of savolitinib + osimertinib combination sometimes may still be potentially beneficial for NSCLC patients with low-GCN-level MET amplification, which may provide some thought-provoking ideas in clinical practice. The gene discussed is MET; the disease is non-small cell lung carcinoma.